Telix ($TLX) BLA Rejection, Manufacturing Deficiencies, and SEC Subpoena Case

S.D. Indiana

Court

1:25-cv-02299

Case number

02/21/2025

Class period Start

08/28/2025

Class period End

01/09/2026

Lead Plaintiff motion deadline

$TLX investors filed a claim against Telix Pharmaceuticals for allegedly overstating its manufacturing readiness, regulatory progress, and product pipeline developments for its prostate and renal cancer programs.
After the company disclosed an SEC subpoena and later received an FDA Complete Response Letter citing manufacturing and compliance issues, $TLX fell 41% from $16.28 on July 22, 2025, to $9.55 on August 29, 2025.
$TLX investors can join this case to be notified about potential recovery.
Case Details:

Between February 21, 2025, and August 28, 2025, Telix told investors it was advancing several oncology programs, including its prostate cancer therapies and TLX250-CDx, a biologic diagnostic for renal cancer. Management described strong progress, highlighted late-stage development across its pipeline, and emphasized its global manufacturing partnerships. The company reported that it had submitted a Biologics License Application (BLA) for TLX250-CDx and portrayed its infrastructure as sufficiently scaled for growth.

According to the complaint, these public statements omitted key information. Telix had received a Refuse to File (RTF) notice from the FDA in July 2024 due to sterility assurance deficiencies related to its manufacturing partners. The company also allegedly knew about compliance weaknesses at two third-party facilities but failed to disclose these to investors. Despite these setbacks, Telix executives continued to express confidence in the company’s regulatory and operational readiness.

On July 22, 2025, Telix revealed that it had received an SEC subpoena related to disclosures about its prostate cancer programs. The stock fell 10.4% on July 23 and an additional 4.7% on July 24. Then, on August 28, 2025, the company announced that the FDA had issued a Complete Response Letter (CRL) identifying chemistry, manufacturing, and controls (CMC) deficiencies, including two Form 483 notices issued to manufacturing partners. On this news, the stock declined another 22%.

Based on these events, $TLX investors filed a claim against Telix Pharmaceuticals, alleging the company:
It failed to disclose known manufacturing and compliance issues at partner facilities.
It misrepresented the status of regulatory submissions and readiness for FDA review.
It reaffirmed pipeline progress and growth strategy without disclosing material risks.
Investors argue Telix’s public statements gave a misleading impression of operational integrity and regulatory progress, which led to losses when the undisclosed risks materialized.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointment

Alleged Offence

Misleading Statements,

Failure to Disclose

Suspected Party

Shareholder

Security Type

Depository Securities (ADS, ADR, GDR)

Trade Direction

Long

Shock Event Date

08/28/2025

Filing date

11/10/2025

Lead Plaintiff Deadline

01/09/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.